Genexine (XKRX:095700) Accounts Payable & Accrued Expense : ₩2,448 Mil (As of Mar. 2024)

View and export this data going back to 2009. Start your Free Trial

What is Genexine Accounts Payable & Accrued Expense?

Genexine's quarterly accounts payable & accrued expense increased from Sep. 2023 (₩4,079 Mil) to Dec. 2023 (₩5,089 Mil) but then declined from Dec. 2023 (₩5,089 Mil) to Mar. 2024 (₩2,448 Mil).

Genexine's annual accounts payable & accrued expense declined from Dec. 2021 (₩21,971 Mil) to Dec. 2022 (₩3,508 Mil) but then increased from Dec. 2022 (₩3,508 Mil) to Dec. 2023 (₩5,089 Mil).

Genexine Accounts Payable & Accrued Expense Historical Data

The historical data trend for Genexine's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genexine Accounts Payable & Accrued Expense Chart

Genexine Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

8,958.95

25,358.34

21,971.39

3,508.35

5,088.68

Genexine Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial															3,089.72	8,154.46	4,078.53	5,088.68	2,448.30

Genexine Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Genexine (XKRX:095700) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genexine Inc (XKRX:095700) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

700 Daewangpangyo-ro, Gyeonggi-do, Korea Bio Park Building B, Bundang-gu, Seongnam-si, KOR, 13488

Website

http://www.genexine.com

Genexine Inc is a clinical-stage biotechnology company. It is focused on the development and commercialization of immunotherapeutics and next-generation long-acting biologics. Its primary technologies are Therapeutic DNA vaccine technology and Hyfc platform. The company's product pipeline includes products such as GX-H9, GX-E2, GX-G3, GX-G6, and Papitrol-188 among others.

Genexine (XKRX:095700) Headlines

No Headlines